Preventive vaccine

Vactech is developing a vaccine for the prevention of Type 1 Diabetes (T1D). This multivalent vaccine is based on a patented composition which makes it effective against those enterovirus types (Coxsackie B serotypes) that link to this disease. In addition, the vaccine is designed to prevent several other enterovirus diseases and possibly also Celiac Disease. Preclinical proof-of-concept studies have confirmed the efficacy and safety of the vaccine and prediction models suggest that it could prevent at least 50% of Type 1 Diabetes cases.

Vaccine strengths

  • Simple product
  • Large target population, *)
  • Strong scientific evidence
  • Patented vaccine composition
  • Proof-of-concept in mouse trials
  • Favorable safety and immunogenicity outcomes in Phase 1 human trial
  • First to the market
  • Product family of vaccines, antivirals and diagnostics

*) Prevention of T1D: The general population or those carrying genetic predisposition to T1D and comprising about 20% of the general Caucasian population. Prevention of acute Coxsackie B virus diseases (e.g. myocarditis, meningitis): The general population and vulnerable population. Prevention of Celiac Disease: The general population or genetic risk groups.

Vactech's diabetes vaccine (PRV-101) is codeveloped with our strategic partner, Provention Bio, a Sanofi Company. It is based on the similar conventional effective and safe technology, which is used in other inactivated enterovirus vaccines such as polio and EV71 vaccines. The PRV-101 vaccine recently passed the First-in-Human Phase 1 trial showing good tolerability and immunogenicity. See publication in Diabetologia, and ClinicalTrials.gov Identifier: NCT04690426.